Denali Therapeutics Inc. — Net Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/12457cc0-2d4b-4c9e-bd44-7ac7bd40264a/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-512.5M | 2025-01-01 – 2025-12-31 | evidence 0001714899-26-000021 |
| FY 2024 | $-422.8M | 2024-01-01 – 2024-12-31 | evidence 0001714899-25-000066 |
| FY 2023 | $-145.2M | 2023-01-01 – 2023-12-31 | evidence 0001714899-24-000086 |
| FY 2022 | $-326.0M | 2022-01-01 – 2022-12-31 | evidence 0001714899-23-000049 |
| FY 2021 | $-290.6M | 2021-01-01 – 2021-12-31 | evidence 0001714899-22-000058 |
| FY 2020 | $71.1M | 2020-01-01 – 2020-12-31 | evidence 0001714899-21-000033 |
| FY 2019 | $-197.6M | 2019-01-01 – 2019-12-31 | evidence 0001714899-20-000026 |
| FY 2018 | $-36.2M | 2018-01-01 – 2018-12-31 | evidence 0001714899-19-000015 |
| FY 2017 | $-88.2M | 2017-01-01 – 2017-12-31 | evidence 0001714899-19-000015 |
| FY 2016 | $-86.7M | 2016-01-01 – 2016-12-31 | evidence 0001714899-19-000015 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Denali Therapeutics Inc. — all facts · Revenue · Operating Income